Abstract: The invention is directed to a process for the catalytic oxidation of an isoprenoid containing at least one allylic hydrogen atom, which process comprises reacting the isoprenoid with oxygen or an oxygen-containing gas in an inert solvent in the presence of a N-hydroxydicarboxylic acid imide of the formula ##STR1## wherein A-B stands for CH.sub.2 -CH.sub.2, CH.dbd.CH, an aromatic hydrocarbon residue or a group derived from one of these groups in which one or more hydrogen atoms is/are replaced by alkyl or halogen,to produce a primary of secondary hydroperoxide.The process of the invention is suitable for the manufacture of steroids, vitamins, odorant substances, carotinoids and the like.

Abstract: Compounds of the formula ##STR1## wherein R.sup.1 -R.sup.4 is hydrogen or chlorine, R.sup.5 is --COOMe or --SO.sub.3 Me, Me is an alkali metal cation and X is oxygen, sulfur or selenium,photosensitizers for the conversion of tachysterol into previtamin D are described. The tachysterol content in mixtures of previtamin D and tachysterol can be greatly reduced by UV-irradiation in the presence of such photosensitizers.

Abstract: Compounds of the formula ##STR1## wherein R.sup.1 -R.sup.4 is hydrogen or chlorine, R.sup.5 is --COOMe or --SO.sub.3 Me, Me is an alkali metal cation and X is oxygen, sulfur or selenium, photosensitizers for the conversion of tachysterol into previtamin D are described. The tachysterol content in mixtures of previtamin D and tachysterol can be greatly reduced by visible light irradiation in the presence of such photosensitizers.

Abstract: Compounds of the formula ##STR1## wherein R.sup.1 and R.sup.2, independently, are hydrogen, halogen or lower alkyl; R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7, independently, are hydrogen or lower alkyl; R.sup.8 is hydrogen, lower alkyl or formyl; R.sup.9 and R.sup.10, independently, are methyl or trifluoromethyl; and n is 0 (zero) or, when both R.sup.7 and R.sup.8 are lower alkyl, n is 0 (zero) or 1, prepared, inter alia, from p-aminobenzaldehydes which may be N-alkyl substituted, are described. The compounds of formula I are orally active antidiabetic agents.

Abstract: Compounds of the formula ##STR1## wherein R.sup.1 and R.sup.2, independently, are hydrogen, halogen or lower alkyl; R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7, independently, are hydrogen or C.sub.1-3 alkyl; R.sup.8 is hydrogen, lower alkyl or formyl; R.sup.9 and R.sup.10, independently, are methyl or trifluoromethyl; and n is 0 (zero) or, when both R.sup.7 and R.sup.8 are lower alkyl, n is 0 (zero) or 1,prepared, inter alia, from p-aminobenzaldehydes which may be N-alkyl substituted, are described. The compounds of formula I are orally active antidiabetic agents.

Abstract: Pyrrolidine derivatives of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as hereinafter described, prepared inter alia from the corresponding pyrrolines, are described. The compounds are useful as analgesic agents.

Abstract: Compounds represented by the formula ##SPC1##Wherein R.sup.1 is a pyridyl, R.sup.2 is hydrogen or lower alkyl, R.sup.3 is hydrogen, lower alkyl or benzyl and R.sup.4 is phenyl or phenyl substituted at one or more carbon atoms with one or more of halogen, lower alkyl, lower alkoxy, nitro or aminoand pharmaceutically acceptable acid addition salts thereof, having analgesic activity are disclosed.